Drugs & TargetsFree Subcutaneous formulation of Darzalex approved by EC for multiple myeloma June 05, 2020Vol.46 No.23
Drugs & TargetsFree Opdivo + Yervoy receive FDA approval combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC May 29, 2020Vol.46 No.22
Drugs & TargetsFree Brigatinib receives FDA approval for ALK-positive metastatic NSCLC May 29, 2020Vol.46 No.22
Drugs & TargetsFree CLR 131 receives fast track designation in lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia May 29, 2020Vol.46 No.22
Drugs & TargetsFree Opdivo + Yervoy combination receives FDA approval for first-line mNSCLC (PD-L1 tumor expression ≥1%) May 22, 2020Vol.46 No.21
Drugs & TargetsFree Pomalidomide receives accelerated approval to for Kaposi sarcoma May 22, 2020Vol.46 No.21
Drugs & TargetsFree Rucaparib receives FDA approval for BRCA-mutated metastatic castration-resistant prostate cancer May 22, 2020Vol.46 No.21
Drugs & TargetsFree Ripretinib receives FDA approval for advanced gastrointestinal stromal tumor May 22, 2020Vol.46 No.21
Drugs & TargetsFree Tecentriq receives FDA approval as first-line monotherapy in NSCLC indication May 22, 2020Vol.46 No.21
Drugs & TargetsFree Olaparib receives FDA approval for HRR gene-mutated metastatic castration-resistant prostate cancer May 22, 2020Vol.46 No.21
